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1. Introduction 
Albright hereditary osteodystrophy (AHO) is a genetic syndrome characterized by a 
distinctive set of developmental and skeletal defects that may easily be misdiagnosed as 
exogenous obesity in children. There are very few publications detailing the comprehensive 
management of children and adolescents with this disorder. This chapter provides a 
comprehensive discussion of the various aspects of this disorder. At the end, the reader 
should be able to: (1) List the clinical features of Albright hereditary osteodystrophy, (2) 
Identify the genetic and molecular abnormalities of AHO, (3) List the clinical features of 
pseudohypoparathyroidism type 1a (PHP 1a), (4) Describe the management of children and 
adolescents with PHP 1a. 
2. Genetics of Albright hereditary osteodystrophy 
The molecular basis for AHO is a heterozygous mutation of the gene that encodes the G-
stimulatory subunit (Gsα) of guanine nucleotide-binding protein—the GNAS gene—that is 
located at chromosome 20q13.2. This type of mutation leads to a loss of expression or 
function of the Gsα which impairs the transmission of stimulatory signals to adenylate 
cyclase, limiting cyclic AMP generation necessary for hormone action(Lietman, 2008). 
The GNAS gene is subject to imprinting. Patients with AHO who have GNAS mutations on 
maternally inherited alleles manifest resistance to multiple hormones, such as parathyroid 
hormone (PTH), thyroid stimulating hormone (TSH), gonadotropins, growth-hormone-
releasing hormone (GHRH), and glucagon(Brickman, 1986; Weinstein, 2004). These defects 
lead to PHP 1a. On the other hand, patients with AHO who have GNAS mutations on 
paternally inherited alleles have only the phenotypic features of AHO without hormonal 
resistance, a condition termed pseudopseudohypoparathyroidism (PPHP) (Lietman, 2008). 
PHP 1b is an autosomal dominant disorder that is associated with the presence of hormone 
resistance that is limited to PTH target organs, normal Gsα activity, and the absence of 
features of AHO(Levine, 1983). PHP 1c is associated with features of AHO, resistance to 
multiple hormones, and normal GNAS activity while PHP type 2 is associated with renal 
resistance to PTH action and the absence of AHO phenotype(Levine, 2000). 
More than 50 different loss-of-function mutations of GNAS have been reported in more 
than 70 affected individuals. Pohlenz et al.(Pohlenz, 2003) have reported a missense 
mutation, which results in the amino-acid substitution (Lys338Asn) in codon 338 of exon 
12 of the GNAS gene associated with congenital hypothyroidism in AHO, though they did 
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not state the precise mechanism by which this mutation leads to hypothyroidism. A Q35X 
mutation in exon 1 has been associated with growth-hormone deficiency(Germain-Lee, 
2003), whereas a de novo, missense mutation, W281R in exon 11, has been linked to 
progressive osseous heteroplasia, a rare, autosomal-dominant condition that presents in 
childhood as dermal ossification that progresses to involve deep skeletal muscles(Chan, 
2004). Germain-Lee et al.(Germain-Lee, 2003) identified a patient with a Q29X mutation, 
and Nwosu et al. (Nwosu, 2009) reported the association of Q29X mutation  with a 
phenotype that includes Albright hereditary osteodystrophy, morbid obesity, acanthosis 
nigricans, insulin resistance, growth-hormone deficiency, hypothyroidism, and 
subcutaneous calcification. 
3. Clinical features 
3.1 General appearance 
The developmental and skeletal defects that characterize AHO include short stocky 
physique (Figure 1a), round face, mental deficiency, heterotopic ossification, and 
brachymetaphalangism(Weinstein, 1993) (Figure 1 b, c). AHO is present in types 1a and 1c 
and PPHP. Hormonal resistance is seen in PHP 1a, PHP 1c and PHP type 2. 
3.2 Stature 
The prevalence of short adult height in PHP 1a is reported to be as high as 80%(Nagant de 
Deuschaisnes, 2007). Although height during childhood may be normal, adult height is 
often subnormal. The reason for the short stature in PHP 1a is multifactorial and includes 
GHRH resistance and chondrocytic dysfunction as explained below in section 3.8.  
3.3 Mental deficiency 
Learning disabilities and psychomotor retardation have been described in PHP 1a(Chen, 
2005). The mechanism of this mental deficiency is unknown and early institution of thyroid 
hormone replacement does not seem to prevent the development of mental 
deficiency(Weisman, 1985). There appears to be a correlation with reduced Gsα since 
patients with PHP 1b do not present with mental deficiency in spite of equivalent serum 
calcium and phosphate abnormalities(Wilson, 1994). This mental deficiency is generally 
mild, but ranges from moderately severe delay to normal educational ability.   
3.4 Ectopic calcification 
In patients with PHP 1a, soft-tissue calcification has been reported in various body parts, 
especially in the subcutaneous tissues, and rarely in the brain and cardiac septum(Schuster, 
1992). Persistent hyperparathyroidism is believed to have some causative role in this 
abnormal calcification. This situation is distinct from progressive osseous heteroplasia 
(Chan, 2004), a rare condition that causes dermal ossification. 
3.5 Brachymetaphalangism 
The hand abnormalities in the PHP and PPHP forms of AHO are indistinguishable 
(Poznanski, 1977). The malformations involve both the phalanges and metacarpals and are 
often symmetrical(Wilson, 1994) (Figure 1b). Shortening of the distal phalanx of the thumb 
is estimated to occur in 75% of AHO patients(Poznanski, 1977). Similar shortening occur in 
the metacarpals. Metacarpal shortening often involves the fourth and the fifth 
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metacarpals(Poznanski, 1977; Steinbach, 1965). Shortening of the metatarsals (Figure 1c), 
especially the third and fourth, is seen in about 70% of persons with AHO(Steinbach, 1966).  
 
 
Fig. 1. a, b, c, d. Features suggestive of Albright hereditary osteodystrophy(Nwosu, 2009) 
Figure 1 | Features suggestive of Albright hereditary osteodystrophy in the patient. a | 
Photo of a patient at 5 years of age showing an obese phenotype, round face, broad chest, 
short neck and digits consistent with pseudohypoparathyroidism type 1a. b | Photo of the 
patient’s hand at 5 years of age showing brachyphalangism of the fingers, especially the 
third through fifth digits. c | Photo of the patient’s feet at 5 years of age showing 
brachyphalangism of the toes. d | Bone age radiograph of the patient at 7 years of age 
showing premature fusion of the epiphyses of the distal phalanges of the thumb, 
midphalanges of both the second and fifth fingers, and shortening of the third through fifth 
metacarpals. Her bone age was read as 13 years at a chronological age of 7 years and 8 
months. 
3.6 Obesity and insulin resistance 
Insulin resistance has not been described in patients with PHP 1a, and acanthosis nigricans 
is not a typical finding in AHO. Germain-Lee et al(Germain-Lee, 2003) reported a patient 
with acanthosis nigricans in a cohort of 13 patients with PHP 1a who had normal 
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hemoglobin A1c and fasting insulin levels. Nwosu et al(Nwosu, 2009) described a child with 
PHP 1a with acanthosis nigricans and insulin resistance (Figure 2). 
A patient with Albright hereditary osteodystrophy-like syndrome with a normal GNAS gene 
that was complicated by type 2 diabetes mellitus with severe insulin resistance, growth-
hormone deficiency and diabetes insipidus has been described(Sakaguchi, 1998). Long et 
al.(Long, 2007) reported that obesity is a more prominent feature of PHP 1a than of PPHP, and 
that severe obesity is characteristic of PHP 1a. They postulated that paternal imprinting of Gsα 
occurs in the hypothalamus such that maternal, but not paternal, Gsα mutations lead to loss of 
the melanocortin signaling cascade, which is important for signaling satiety. This loss of satiety 
signaling then leads to greater alteration in energy balance and notably greater insulin 
resistance in individuals with PHP 1a (as shown in Figure 2) than in those with PPHP. 
 
 
Fig. 2. Acanthosis nigricans of the neck folds in a patient with Albright Hereditary 
Osteodystrophy(Nwosu, 2009) 
The insulin receptor belongs to a large class of tyrosine kinase receptors, and is 
structurally distinct from the heptahelical Gs receptors. The development of insulin 
resistance in the patient shown in Figure 2 most probably resulted from the combined 
effects of obesity, growth-hormone treatment, a family history of type 2 diabetes mellitus, 
and abnormal melanocortin signaling, as noted above. Obesity is the most common cause 
of insulin resistance in children(Caprio, 2002). It is postulated to represent a subclinical 
inflammatory state that promotes the production of proinflammatory factors, such as 
interleukin 6 and tumor necrosis factor, which are involved in the pathogenesis of insulin 
resistance(Bastard, 2006). Growth hormone antagonizes insulin's effects on glucose 
metabolism by inhibiting insulin-induced glucose uptake through the inhibition of insulin 
receptor substrate-2-associated phosphatidylinositol-3-kinase activity, without affecting 
glucose transporter 4 translocation(Sasaka-Suzuki N, 2009). A family history of type 2 
diabetes mellitus conveys not only heritable genetic information, but also reveals familial 
behaviors and social norms that may exacerbate the individual's risk for insulin resistance 
and frank diabetes(Meigs, 2008). 
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3.7 Biochemical profile 
The biochemical profile in patients with PHP 1a shows evidence of PTH resistance, with 
elevated serum concentrations of PTH and phosphate, and low or normal serum levels of 
ionized calcium. Serum TSH concentrations are elevated from infancy indicating TSH 
resistance at the receptor-complex level. Subnormal peak growth-hormone levels of <7.5 
µg/l are commonly found when growth-hormone stimulation tests are carried out(Scott, 
1995). Serum gonadotropins are either normal or slightly elevated in women with AHO 
despite their hypoestrogenic status(Namnoum, 1998). This is believed to be due to partial 
resistance to gonadotropins in the granulosa and theca cells of the ovary(Namnoum, 1998).  
3.8 Bone age and other skeletal and radiologic features 
The bone ages of children with PHP 1a are more advanced than would be expected for their 
stage of sexual maturation. Premature epiphyseal fusion occurs selectively in the hands and 
feet of affected patients(de Wijn, 1982; Steinbach, 1966). Furthermore, the phalanges of 
patients either lack epiphyses or have epiphyses that are partially fused when they first 
develop, which makes accurate assessments of bone age very difficult(Steinbach, 1966). This 
abnormal epiphyseal fusion is postulated to result from the loss of Gsα, which induces 
resistance to parathyroid-hormone-related protein which, in turn, promotes premature 
differentiation of proliferating chondrocytes into hypertrophic chondrocytes(Kobayashi, 
2002; Tavella, 2004; van der Eerden, 2000). This series of events leads to early closure of the 
growth plate and limb-reduction defects. Despite early fusion of the epiphyses in the 
phalanges, the epiphyses of long bones may remain open, thus an increase in height with 
growth-hormone therapy is still possible. 
Other radiological features of PHP 1a in children include rickets which results from low 
levels of 1,25-dihydroxyvitamin D as a result of PTH resistance(Wilson, 1994). Generalized 
osteoporosis and osteitis fibrosa cystica(Burnstein, 1985; Steinbach, 1966) can be seen, and 
these pathologies are suggestive of some preservation of the skeletal remodeling response to 
the raised levels of circulating PTH(Kerr, 1987). Some of the skeletal abnormalities 
associated with AHO include shortened ulna, radial and tibial bowing, coxa vara, coxa 
valga and caudal narrowing of interpedicular distance(Wilson, 1994).  
3.9 Hormonal defects and manifestations 
In addition to the AHO phenotype, biochemical and hormonal derangements in PHP 1a 
lead to characteristic patterns of presentation.  PHP 1a is associated with resistance to 
multiple hormones, such as PTH, TSH, gonadotropins, growth-hormone-releasing hormone, 
and glucagon(Brickman, 1986; Weinstein, 2004). 
PHP 1a accompanied by growth-hormone deficiency was first described in 1995(Scott, 1995). 
The short stature of patients with PHP 1a results from a combination of several factors, such 
as epiphyseal defects and resistance to GHRH(Scott, 1995). This hormone resistance results 
in the inability of GHRH to stimulate pituitary somatotropes to produce growth hormone. 
Many patients with PHP 1a present with subclinical hypothyroidism in infancy (Pohlenz, 
2003; Scott, 1995), as a result of resistance to TSH action. Resistance to PTH action could lead 
to hypocalcemia which could be complicated by hypocalcemic seizures, and/or muscle 
spasms. Resistance to the actions of the gonadotropins results in hypogonadism or 
menstrual irregularities in women with PHP 1a. The mechanism of this reproductive 
dysfunction is believed to be due to a partial resistance of the theca and granulosa cells of 
the ovary to gonadotropins due to deficient Gsα activity (Namnoum, 1998).  
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Whereas resistance to PTH, TSH, growth-hormone-releasing hormone, follicle-stimulating 
hormone, and luteinizing hormone may lead to clinical manifestations, the blunted cyclic 
AMP response to glucagon documented by Brickman et al.(Brickman, 1986) in patients with 
PHP 1a is apparently subclinical, as the glucose response is intact.  
4. Differential diagnosis 
The differential diagnoses of a child with this AHO phenotype include exogenous obesity, 
Cushing syndrome, severe hypoparathyroidism, Prader–Willi syndrome, and Laurence–
Moon–Biedl–Bardet syndrome.  
The generalized metacarpal and phalangeal shortening characteristics of acrodysostosis has 
been observed in cases of AHO(Ablow, 1977). Acrodysostosis presents with similar features 
as AHO including short stature, brachymetaphalangism, advanced bone age, mental 
deficiency and other radiologic features. However, cutaneous ossification does not occur in 
acrodysostosis, and pronounced nasal hypoplasia is a distinguishing feature of 
acrodysostosis, but has been described in PHP 1a(Ablow, 1977). 
Turner syndrome and multiple familial exostoses are associated with short stature and 
metacarpal shortening  but are easily distinguished from AHO(Wilson, 1994).  
A diagnosis is usually reached by reviewing patient’s family history, establishing the 
components of the AHO phenotype, such as short fourth metacarpals, and connecting these 
findings to the existing hormonal defects such as a history of subclinical hypothyroidism or 
parathyroid hormone resistance. 
5. Treatment and management 
The defect in PHP 1a leads to resistance to multiple hormones that mediate their actions 
through cyclic AMP(Spiegel, 1982). These include PTH, TSH, growth-hormone-releasing 
hormone, gonadotropins, glucagon, and possibly TSH-releasing hormone(Balavoine, 2008). 
Patients with Gsα deficiency could, therefore, develop hypothyroidism, hypogonadism, 
growth-hormone deficiency, and pseudohypoparathyroidism, depending on the degree of 
Gsα activity in  specific tissues(Scott, 1995). 
5.1 Hypoparathyroidism 
The initial medical management of all patients with severe, symptomatic hypocalcemia 
should be with intravenous calcium. The recommended initial dose for newborn babies , 
infants and children is 0.5–1.0 ml/kg of 10% calcium gluconate administered over 5 min. 
Administration of oral calcium and 1α-hydroxylated vitamin D metabolites, such as 
calcitriol, is recommended for patients with symptomatic hypocalcemia. The goals of 
therapy are to maintain serum total and ionized calcium levels within the reference range 
and to reduce PTH levels to near normal. This normalization is important because elevated 
PTH levels in patients with PHP 1a could cause increased bone remodeling and lead to 
secondary hyperparathyroid bone disease(Abraham, 2007). 
5.2 Growth-hormone deficiency 
Some children with PHP 1a have hypothalamic growth-hormone deficiency and may benefit 
from therapy with recombinant human growth hormone to achieve optimal adult height. In 
those patients in whom defective growth-hormone secretion is suspected, the epiphyseal 
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defects, commonly mischaracterized as bone-age advancement, should not disqualify these 
children from being considered for growth-hormone therapy. In addition to its effect on 
statural growth, growth-hormone therapy also seems to improve body composition in 
patients with PHP 1a(Nwosu, 2009). 
5.3 Hypothyroidism  
Most patients with PHP 1a present with subclinical hypothyroidism before the onset of 
hypocalcemia. Hypothyroidism is treated with thyroid hormone replacement using 
levothyroxine at age-appropriate and weight-appropriate doses. The aim of management is 
to normalize serum concentrations of TSH and free T4. 
5.4 Hypogonadism 
Common reproductive dysfunctions in persons with PHP 1a include delayed puberty, 
oligomenorrhea and infertility(Abraham, 2007). Each condition requires age-appropriate 
therapy; for example, low-dose estrogenic formulations are used to induce puberty in 
adolescent girls with delayed puberty. 
5.5 Obesity and insulin resistance 
Patients with PHP 1a who also have a family history of type 2 diabetes mellitus may have 
familial risk factors for development of insulin resistance, prediabetes and type 2 diabetes 
mellitus. Growth-hormone therapy improves body composition, but may worsen insulin 
resistance. Lifestyle modifications should be incorporated in the management of patients 
with PHP 1a phenotype who may be at risk of metabolic syndrome. Early introduction of 
oral insulin-sensitizing agents, such as metformin, may be necessary when lifestyle 
modification is ineffective, especially in patients with prediabetes. 
6. Conclusion 
Accurate understanding of the features of AHO will prevent its misdiagnosis as exogenous 
obesity. Children diagnosed with PHP 1a should be further evaluated for associated 
endocrinopathies, such as resistance to growth-hormone-releasing hormone, which may 
lead to growth-hormone deficiency. Preliminary data suggest that the short stature in 
patients with PHP 1a may be ameliorated with growth-hormone therapy in some 
cases(Scott, 1995). The advanced bone age seen in PHP 1a is due to a chondrocytic signaling 
defect, and not due to excess production of sex hormones; therefore, bone-age advancement 
should not preclude affected children from being considered for growth-hormone therapy. 
However, a combination of growth-hormone therapy, family history of type 2 diabetes 
mellitus, and obesity in these children might lead to metabolic complications, such as 
insulin resistance, prediabetes and type 2 diabetes mellitus. 
7. Future directions 
A comprehensive management of a child with PHP 1a must address the controversies 
surrounding authorization of growth hormone therapy for these patients. This is because 
most health insurance carriers decline authorization for GH therapy in these patients 
because of the apparent bone age advancement that affects the digital bones but not the long 
bones.  
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It is equally important to address increasing weight gain in these patients as they are at risk 
for obesity and its co-morbidities. Even though insulin resistance is not part of the 
syndrome, there are increasing reports of worsening insulin resistance in these patients 
which predisposes them to frank diabetes mellitus. This is due to the synergistic effects of 
prevalent obesity and the pre-existing AHO phenotype. 
The presence of delayed puberty may indicate LH and FSH resistance in these patients. 
There is no clear protocol for initiating sex hormone therapy in these patients. Most 
pediatric endocrinologists address this problem by adopting similar therapeutic modalities 
for the induction of the development of secondary sexual characteristics as in patients with 
Turner syndrome.  
Most patients with PHP 1a have variable levels of mental deficiency. It is important to 
address this problem very early in life by recommending additional classroom supervision, 
and in severe cases, instituting an individualized educational plan.  
In summary, a comprehensive management of a patient with PHP 1a includes a thorough 
assessment for associated hormonal defects, the obese phenotype and its comorbidities, and 
the degree of intellectual deficiency. 
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